Which decision rules meet methodological standards in children with febrile neutropenia? Results of a systematic review and analysis

Pediatric Blood and Cancer

Volumn 61, Issue 10, 2014, Pages 1786-1791

  Delebarre, Mathilde ^a   Macher, Emilie ^a   Mazingue, Françoise ^a   Martinot, Alain ^a   Dubos, François ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Children; Decision rules; Fever; Methodology; Neutropenia; Review

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN;

ACUTE LEUKEMIA; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CHILDHOOD CANCER; CHILDHOOD DISEASE; CHILL; FEBRILE NEUTROPENIA; FEVER; HUMAN; HYPOTENSION; INFECTIOUS COMPLICATION; LEUKOCYTE COUNT; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STANDARD; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; VIRUS INFECTION;

CHILDREN; DECISION RULES; FEVER; METHODOLOGY; NEUTROPENIA; REVIEW;

ANTINEOPLASTIC AGENTS; CHILD; DECISION SUPPORT TECHNIQUES; FEBRILE NEUTROPENIA; HUMANS; MEDICAL ONCOLOGY; PEDIATRICS;

EID: 84908519239     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25106     Document Type: Article

References (42)

1. Simon A, Ammann RA, Bode U, et al. Healthcare-associated infections in pediatric cancer patients: Results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect Dis 2008; 8:70.
2. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56-e93.
3. Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008; 26:606-611.
4. Sung L, Feldman BM, Schwamborn G, et al. Inpatient versus outpatient management of low-risk pediatric febrile neutropenia: Measuring parents and healthcare professionals' preference. J Clin Oncol 2004; 22:3922-3929.
5. Irfan S, Idrees F, Mehraj V, et al. Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: A descriptive study. BMC Infect Dis 2008; 8:80.
6. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 1997; 99:580-588.
7. Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2012; 30:4427-4438.
8. Macher E, Dubos F, Garnier N, et al. Predicting the risk of severe bacterial infection in children with chemotherapy-Induced febrile neutropenia. Pediatr Blood Cancer 2010; 55:662-667.
9. Miedema KG, de Bont ES, Oude Nijhuis CS, et al. Validation of a new risk assessment model for predicting adverse events in children with fever and chemotherapy-induced neutropenia. J Clin Oncol 2011; 29:e182-e184.
10. Phillips RS, Lehrnbecher T, Alexander S, et al. Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS ONE 2012; 7:e38300.
11. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 2009; 62:1006-1012.
12. McGinn T, Guyatt G, Wyer P, et al. Diagnosis: Clinical prediction rules. In: Guyatt G, Rennie D, editors. " Users' guides to the medical literature", a manual for evidence-based clinical practice. Chicago, IL: American Medical Association; 2002. pp 471-483.
13. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA 1997; 277:488-494.
14. Maguire JL, Kulik DM, Laupacis A, et al. Clinical prediction rules for children: A systematic review. Pediatrics 2011; 128:e666-e677.
15. Tezcan G, Kupesiz A, Ozturk F, et al. Episodes of fever and neutropenia in children with cancer in a tertiary care medical center in Turkey. Pediatr Hematol Oncol 2006; 23:217-229.
16. West DC, Marcin JP, Mawis R, et al. Children with cancer, fever and treatment-induced neutropenia: Risk factors associated with illness requiring the administration of critical care therapies. Pediatr Emerg Care 2004; 20:79-84.
17. Wicki S, Keisker A, Aebi C, et al. Risk prediction of fever in neutropenia in children with cancer: A step towards individually tailored supportive therapy? Pediatr Blood Cancer 2008; 51:778-783.
18. Alexander SW, Wade KC, Hibberd PL, et al. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2002; 24:38-42.
19. Aquino M, Herrera L, Sandler ES, et al. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 2000; 88:1710-1714.
20. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86:126-134.
21. Paganini H, Rodriguez-Brieshcke T, Zubizarreta P, et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer 2001; 91:1563-1567.
22. Oude Nijhuis C, Kamps WA, Daenen SM, et al. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 2005; 23:7437-7444.
23. Santolaya ME, Alvarez AM, Aviles CL, et al. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia and fever: A prospective, multicenter trial. Pediatr Infect Dis J 2008; 27:538-543.
24. Paganini H, Caccavo J, Aguirre C, et al. A scoring system to predict superinfections in high-risk febrile neutropenic children with cancer. Bol Med Hosp Infant Mex 2011; 68:36-43.
25. Madsen K, Rosenman M, Hui S, et al. Value of electronic data for model validation and refinement: Bacteremia risk in children with fever and neutropenia. J Pediatr Hematol Oncol 2002; 24:256-262.
26. Santolaya ME, Alvarez AM, Avilés CL, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever and neutropenia. Clin Infect Dis 2002; 35:678-683.
27. Santolaya ME, Alvarez AM, Avilés CL, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 2004; 22:3784-3789.
28. Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996; 14:919-924.
29. Baorto EP, Aquino VM, Mullen CA, et al. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer 2001; 92:909-913.
30. Ammann RA, Hirt A, Lüthy AR, et al. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia. Pediatr Infect Dis J 2004; 23:61-67.
31. Agyeman P, Aebi C, Hirt A, et al. Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: Results of the prospective multicenter SPOG 2003 FN study. Pediatr Infect Dis J 2011; 30:e114-e119.
32. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 2001; 19:3415-3421.
33. Klaassen RJ, Goodman TR, Pham B, et al. " Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18:1012-1019.
34. Ammann RA, Hirt A, Lüthy AR, et al. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 2003; 41:436-443.
35. Rondinelli PI, Ribeiro Kde C, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol 2006; 28:665-670.
36. Hakim H, Flynn PM, Srivastava DK, et al. Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2010; 29:53-59.
37. Badiei Z, Khalesi M, Alami MH, et al. Risk factors associated with life-threatening infections in children with febrile neutropenia: A data mining approach. J Pediatr Hematol Oncol 2011; 33:e9-e12.
38. Paganini HR, Aguirre C, Puppa G, et al. A prospective multicentric scoring system to predict mortality in febrile neutropenic children with cancer. Cancer 2007; 109:2572-2579.
39. Ammann RA, Bodmer N, Hirt A, et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: The prospective multicenter SPOG 2003 FN study. J Clin Oncol 2010; 28:2008-2014.
40. Geneviève F, Godon A, Marteau-Tessier A, et al. [Automated hematology analysers and spurious counts Part 2. Leukocyte count and differential]. Ann Biol Clin (Paris) 2012; 70:141-154.
41. Phillips RS, Wade R, Lehrnbecher T, et al. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med 2012; 10:6.
42. Semeraro M, Thomée C, Rolland E, et al. A predictor of unfavourable outcome in neutropenic paediatric patients presenting with fever of unknown origin. Pediatr Blood Cancer 2010; 54:284-290.